In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens

E-ISSN： 1873-4286|17|27|2881-2888

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.27, 2011-09, pp. : 2881-2888

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fixed-Dose Combination Drugs for Tuberculosis: Application in Standardised Treatment Regimens

By Blomberg B.

Drugs, Vol. 63, Iss. 6, 2003-01 ,pp. : 535-553

Adis International

Access to resources Recommend Favorite

In vitro and in vivo metabolism of emerging drugs of abuse

By Meyer Markus R.

PHARMAKON, Vol. 1, Iss. 6, 2013-11 ,pp. : 491-496

Govi-Verlag

Access to resources Recommend Favorite

Predictive In Vitro Models of the Sterilizing Activity of Anti-Tuberculosis Drugs

Current Pharmaceutical Design, Vol. 10, Iss. 26, 2004-10 ,pp. : 3285-3295

Bentham Science Publishers

Access to resources Recommend Favorite

In Vitro and In Vivo Activities of Acylated Derivatives of Isoniazid Against Mycobacterium Tuberculosis

By HEARN MICHAEL CYNAMON MICHAEL

Drug Design and Discovery, Vol. 18, Iss. 4, 2003-01 ,pp. : 103-108

Taylor & Francis Ltd

Access to resources Recommend Favorite

The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy

Current Pharmaceutical Design, Vol. 20, Iss. 39, 2014-12 ,pp. : 6191-6206

Bentham Science Publishers

Access to resources Recommend Favorite